National Center for Therapeutics Manufacturing (NCTM)’s Post

🎉 Vellum Biotechnology won a $300,000 award from the U.S. Department of Health and Human Services (HHS)' The National Institutes of Health ! 🌟 This #SBIR #STTR award is for the development of a GMP EDHFR vector to monitor investigational CAR T cell therapies. 💡 The goal is to create a modular imaging vector that can be applied to different cellular therapies to track their biodistribution over time. 💻 This project is part of the Small Technology Transfer Research Program Phase I and will last for 0.92 years, starting from August 7, 2024, to July 31, 2025. #innovation #biotech #celltherapy #imaging

#DrugDiscovery Bina - Bridge Innovate Nurture Advance Launched a New Track for Drug Discovery. We announce the launch of a new track for drug discovery at Bina. This initiative aims to bring together Weizmann Institute of Science scientists and world-class experts from the #pharmaceutical and #drug development industries, as well as #clinical practice. Harnessing Weizmann’s deep and innovative basic science research into the discovery of #disease #mechanisms and #molecular and #cellular pathways can lead to the development of new targets and #therapeutic agents. We would like to thank our SAB committee for their significant contribution: Isaac Kohlberg from Harvard University, Aya Jakobovits; Opher Shapira, CEO of YEDA - Technology Transfer Company of Weizmann Institute of Science and Irit Sagi, VP Innovation and Technolgy Transfer at the Weizmann Institute. #Innovation #DrugDiscovery #BiomedicalResearch #TranslationalScience #WeizmannInstitute #Bina Sharon Fireman, Merav Marom, Hezi Sztainberg, Ph.D., Opher Shapira, Elik Chapnik, Yael Klionsky, Reut Magor, Orel Yaverbaum, Irit Sagi

Word-up my fellow space medicine nerds! Thank you to everyone who made the IAC2024 conference a success! For those interested, mark your calendars for a free webinar on October 29th discussing "The Future of Medicine and Biotechnology In Space." Learn about the exciting opportunities for industrial pharmaceutical and biomanufacturing in microgravity. Pings to: Ivy Mayor Johannes N. Svensøy Michail Magkos and Shawna Pandya, MD #SpaceMedicine #Medicine #Microgravity

Today, TrialKey attended the BioConnect: Australia-Taiwan Biotech Forum at the Centre for Eye Research Australia (CERA), hosted by Southern Taiwan Science Park, the Development Center for Biotechnology, and Australian Trade and Investment Commission (Austrade). The event brought together 12 pioneering Taiwanese biotech companies, including ACRO Biomedical Co., Ltd., KriSan Biotech Co., Ltd., and UNICOCELL Biomed, each advancing innovative solutions from regenerative medicine to RNA therapeutics. TrialKey had the opportunity to engage in one-on-one meetings with these companies, showcasing our AI-powered biostatistical validation and clinical trial simulation services. This experience underscored our commitment to bridging international clinical research partnerships and exploring collaborative synergies. Book a demo: https://appt.link/minhthu Marketing and Opyl investor enquiries: bernice@trialkey.ai #biotechnology #clinicalresearch #biotech #medtech #healthtech #regenerativemedicine #australiabiotech #biostatistics #clinicaltrials #austrade #bioconnect #ai

Dr Adriana Kiędzierska - Mencfeld, Chief Integration Officer, will share her extensive experience in #biomanufacturing during upcoming #CEBioForum2024 conference.  Adriana will take part in the discussion "How to handle biomanufacturing?" #BiotechConference  #Biomanufacturing #CEBioForum2024 #Panelist #Innovation #PolpharmaBiologics

The same molecular complexity that makes biotherapeutics effective treatments also poses a significant challenge at the manufacturing level 💡 Sean Keng Rui Chia, Senior Scientist at the A*STAR Bioprocessing Technology Institute (BTI), has been working alongside fellow researchers to overcome this hurdle. “At BTI, we’re studying the developability properties—such as the specificity and aggregation propensity—of next-generation antibody therapeutics like multispecific antibodies,” he shared with A*STAR Research. “As part of this work, we design new assays and computational models to assess these therapeutic molecules and optimise their properties.” 🌟 In 2022, Chia was awarded the prestigious Singapore Biodesign Innovation Fellowship, which opened the door for him to explore the world of health and medtech innovation with the support of experienced mentors. Head to the comments section for the link to the full story 👇 --- #scicomm #science #technology #STEM #research #innovation #ASTAR #biotherapeutics #biologics #healthcare #HHP #industry #Singapore

🔬 Exciting Partnership Alert: NovAliX Teams Up with Bruker BioSpin to Revolutionise Drug Discovery! 🌟 French preclinical CRO NovAliX has announced a strategic partnership with Massachusetts-based Bruker Corporation, marking a significant step forward in drug discovery. Bruker has made a minority investment in NovAliX, setting the stage for a powerful collaboration that aims to push the boundaries of biophysics and structural biology. 🧬 Leveraging Bruker’s cutting-edge analytical technologies, this partnership is focused on discovering new drug targets, optimizing drug candidates, and predicting potential failures earlier in the process. With shared expertise, NovAliX and Bruker will advance methods in functional structural biology, molecular dynamics, drug binding, and more. This collaboration strengthens NovAliX's leadership in the field and promises to bring innovative solutions to the world of drug discovery. Stay tuned for more breakthroughs! 🚀 #NovAliX #Bruker #DrugDiscovery #Biophysics #StructuralBiology #Pharma #Biotech #Innovation #Partnerships

Advancing #celltherapy: innovations in #polymer-based #encapsulation and delivery #Biopolymers are increasingly explored as a versatile platform to enhance therapeutic efficacy of cell therapies through controlled delivery. Next month, Joshua Katz (Senior R&D Manager, IFF Pharma), Marizela Delic-Schlumbohm (Senior R&D Manager – NovaMatrix®, IFF Pharma), Yevgeny Brudno (Associate Professor, University of North Carolina - Chapel Hill and North Carolina State University - Raleigh), Omid Veiseh (Director, Rice Biotech Launch Pad), Tom Kamperman (CTO & Founder, IamFluidics BV) will delve into the critical aspects of scalability and reproducibility in polymer-based encapsulation systems Attend this webinar to learn about: • Why controlled delivery vehicles in #cellulartherapies are critical • The key characteristics of ultrapure #biopolymers, which can play a pivotal role in ensuring cell viability and controlled delivery • Critical aspects of scalability and reproducibility in polymer-based encapsulation systems, essential for translating research breakthroughs into practical clinical applications Register for this #webinar below:

🚀 🚀 We are very pleased to announce that we achieved our first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with EFS (French Blood Establishment) with unprecedented yields 🚀🚀   ✅ The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods. ✅ This innovation has just been tech-transferred and validated in a GMP-grade biomanufacturing environment. ✅ This first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its lead drug candidate EVerGelTM. 👉 For more information, please find below the press release. EVerZom EFS Nicolas Rousseau Hélène R. #bioproduction #exosomes #biotech #innovation

Collaborations are essential for driving innovation and advancing scientific discoveries in #proteomics. Therefore, we’re excited to strengthen our collaboration with SCIEX.   This expanded partnership enables us to deliver even more cutting-edge, high-throughput proteomics solutions with greater flexibility and performance. The proven power of Evosep One with the advanced capabilities of the ZenoTOF 7600+, enable labs to process up to 500 samples per day with reduced system downtime. Tailored for robustness, this system minimizes sample carryover and maximizes data quality, making it an invaluable tool for advancing proteomics in pharma and biotechnology.   “Over the past 3 years, we are excited to see this collaboration grow to encompass more of the SCIEX portfolio. This latest achievement will allow scientist to harness the power of ZT Scan DIA data to precisely quantify proteins with up to 10-fold improvement in throughput for protein quantitation. Utilizing the Evosep One with SPD methods provides the speed and flexibility of analysis which perfectly matches with the performance of ZT Scan DIA. Together, SCIEX and Evosep can work together to help advance clinical proteomic research,” said Jose Castro-Perez, Vice President, Product Management.   Learn more in this recent press release from SCIEX: https://lnkd.in/dMYew8JY #pressrelease #scientificdiscoveries #technology #LCMS